Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus DEB-TACE in BCLC Stage A/B HCC
NCT04174781Phase 2Unknown
- Sponsor
- Zhejiang University
- Start
- Nov 2019
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoint: Progression-Free Survival at 36 months. Status: unknown.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04174781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174781.